SCHEMBL6054650

SCHEMBL6054650

CON(C)C(=O)c1ccc2c(c1)n(C)c(=O)n2C(C)C

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPD P32754 5/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ BRD4 O60885 2/20 0.43
▸ BRPF1 P55201 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ GLA P06280 1/20 0.41
▸ SLC22A12 Q96S37 1/20 0.40
▸ MAPK14 Q16539 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ MLYCD O95822 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24815337 0.81 HPD (0.52) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL30048876 0.81 HPD (0.52) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL30049030 0.79 SLC22A12 (0.57) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL24815336 0.79 SLC22A12 (0.57) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL24812336 0.79 HPD (0.55) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL25139613 0.78 HPD (0.54) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL6054646 0.76 POLB (0.56) ALDH1A1KDM4EHSD17B10GLAMLYCD
SCHEMBL25139664 0.76 HPD (0.52) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL5836096 0.76 HPD (0.52) HPDSMN1; SMN2ALDH1A1BRD4BRPF1
SCHEMBL6054648 0.75 HPD (0.46) HPDSMN1; SMN2ALDH1A1BRD4BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1708709-A1 METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS Pfizer Products Incorporated (US) 2006-10-11 — — EP disclosed
US-20050153985-A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors KEHRLI MARCUS E JR (US) 2005-07-14 — — US disclosed
WO-2005060967-A1 METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2005-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153985-A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors MAPK1, MAPKAPK2, MAP3K2 HPD 3336/4885SMN1; SMN2 4199/4885ALDH1A1 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback